|

Panitumumab Clinical Trials

22 actively recruiting trials across 9 locations

Also known as: ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, E7.6.3, Human IgG2K Monoclonal Antibody +6 more

Pipeline

Phase 1: 4Phase 2: 9Phase 3: 6Phase 1/2: 3

Top Sponsors

  • Amgen3
  • National Cancer Institute, Naples2
  • National Cancer Institute (NCI)2
  • Vanderbilt-Ingram Cancer Center1
  • UNICANCER1

Indications

  • Cancer22
  • Metastatic Colorectal Cancer4
  • Colorectal Cancer3
  • Lung Cancer3
  • Liver Disease2

Other8 trials

Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
Phase 2
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
Phase 3
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Phase 2
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
Phase 2
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Phase 3
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2
The Sagittarius Trial
Phase 3
ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer
Phase 2

Birmingham, Alabama3 trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

University of Alabama at Birmingham Cancer Center

Phase 2
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

University of Alabama at Birmingham Cancer Center

Phase 3
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

University of Alabama at Birmingham Cancer Center

Phase 2

Duarte, California2 trials

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

City of Hope National Medical Center /ID# 270255

Phase 2
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

City of Hope National Medical Center

Phase 1

Palo Alto, California2 trials

Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

Stanford University School of Medicine

Phase 1/2
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Stanford University, School of Medicine

Phase 1/2

Nashville, Tennessee2 trials

(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

Vanderbilt University/Ingram Cancer Center

Phase 1
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

Vanderbilt University/Ingram Cancer Center

Phase 1

Anchorage, Alaska1 trial

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Anchorage Associates in Radiation Medicine

Phase 3

Chandler, Arizona1 trial

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Ironwood Cancer and Research Centers Scottsdale

Phase 3

Gilbert, Arizona1 trial

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Banner Health- MD Anderson Cancer Center

Phase 1/2

Atlanta, Georgia1 trial

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Winship Cancer Institute at Emory University

Phase 1

Houston, Texas1 trial

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

University of Texas MD Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.